Related Experiment Video
Updated: Nov 18, 2025
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
20.5K
Pulmonary arterial hypertension in systemic sclerosis
Benoît Lechartier1, Marc Humbert2
1Lausanne University Hospital, Department of Respiratory Medicine, Lausanne, Switzerland.
Presse Medicale (Paris, France : 1983)
|February 6, 2021
Summary
Systemic sclerosis (SSc) can lead to pulmonary arterial hypertension (PAH), a severe complication. Early diagnosis and novel treatments targeting pulmonary vascular remodeling are crucial for managing SSc-PAH.
Area of Science:
- Cardiology
- Rheumatology
- Pulmonology
Background:
- Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc).
- It arises from combined vasculopathy and fibrogenesis, posing diagnostic and therapeutic challenges.
- Expert PAH center referral is essential for timely management.
Purpose of the Study:
- To highlight the challenges in early diagnosis and treatment of SSc-PAH.
- To underscore the need for evolving diagnostic algorithms.
- To emphasize the requirement for novel therapeutic strategies targeting pulmonary vascular remodeling.
Main Methods:
- Review of current diagnostic algorithms for SSc-PAH.
- Analysis of therapeutic options for pulmonary vascular remodeling.
- Discussion of challenges in early detection and management.
Main Results:
- SSc-PAH diagnosis and treatment remain challenging.
- Diagnostic approaches have evolved over the past decade.
- There is an unmet need for innovative treatments.
Conclusions:
- Effective management of SSc-PAH requires early diagnosis and expert care.
- Advancements in diagnostic tools are ongoing.
- Novel therapies targeting pulmonary vascular remodeling are essential for improving outcomes in SSc-PAH patients.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
415
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
415
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
333
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
333
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
313
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
313
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
283
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
283
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
431
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
431
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
3.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
3.7K